Literature DB >> 18286310

DFT-based molecular modeling and vibrational study of the La(III) complex of 3,3'-(benzylidene)bis(4-hydroxycoumarin).

Tzvetan Mihaylov1, Natasha Trendafilova, Ivelina Georgieva.   

Abstract

Molecular modeling of the La(III) complex of 3,3'-(benzylidene)bis(4-hydroxycoumarin) (PhDC) was performed using density functional theory (DFT) methods at B3LYP/6-31G(d) and BP86/TZP levels. Both Stuttgart-Dresden effective core potential and ZORA approximation were applied to the La(III) center. The electron density distribution and the nucleophilic centers of the deprotonated ligand PhDC(2-) in a solvent environment were estimated on the basis of Hirshfeld atomic charges, electrostatic potential values at the nuclei, and Nalewajski-Mrozek bond orders. In accordance with the empirical formula La(PhDC)(OH)(H(2)O), a chain structure of the complex was simulated by means of two types of molecular fragment: (1) two La(III) cations bound to one PhDC(2-) ligand, and (2) two PhDC(2-) ligands bound to one La(III) cation. Different orientations of PhDC(2-), OH(-) and H(2)O ligands in the La(III) complexes were investigated using 20 possible [La(PhDC(2-))(2)(OH)(H(2)O)](2-) fragments. Energy calculations predicted that the prism-like structure based on "tail-head" cis-LML2 type binding and stabilized via HO...HOH intramolecular hydrogen bonds is the most probable structure for the La(III) complex. The calculated vibrational spectrum of the lowest energy La(III) model fragment is in very good agreement with the experimental IR spectrum of the complex, supporting the suggested ligand binding mode to La(III) in a chain structure, namely, every PhDC(2-) interacts with two La(III) cations through both carbonylic and both hydroxylic oxygens, and every La(III) cation binds four oxygen atoms of two different PhDC(2-).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18286310     DOI: 10.1007/s00894-008-0277-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  20 in total

1.  Density-functional approximation for the correlation energy of the inhomogeneous electron gas.

Authors: 
Journal:  Phys Rev B Condens Matter       Date:  1986-06-15

Review 2.  Warfarin and vitamin K.

Authors:  J W Suttie
Journal:  Clin Cardiol       Date:  1990-04       Impact factor: 2.882

Review 3.  Synthetic and natural coumarins as cytotoxic agents.

Authors:  Irena Kostova
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-01

4.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.

Authors:  J A Parrish; T B Fitzpatrick; L Tanenbaum; M A Pathak
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

5.  New metal complexes of 4-methyl-7-hydroxycoumarin sodium salt and their pharmacological activity.

Authors:  I P Kostova; I I Manolov; I N Nicolova; N D Danchev
Journal:  Farmaco       Date:  2001-09

6.  Cytotoxic activity of new lanthanum (III) complexes of bis-coumarins.

Authors:  Irena Kostova; Georgi Momekov; Maya Zaharieva; Margarita Karaivanova
Journal:  Eur J Med Chem       Date:  2005-03-02       Impact factor: 6.514

7.  Studies on the cytostatic and cytotoxic effects and mode of action of 8-nitro-7-hydroxycoumarin.

Authors:  D Egan; P James; D Cooke; R O'Kennedy
Journal:  Cancer Lett       Date:  1997-10-14       Impact factor: 8.679

8.  New zirconium (IV) complexes of coumarins with cytotoxic activity.

Authors:  I Kostova; G Momekov
Journal:  Eur J Med Chem       Date:  2006-05-12       Impact factor: 6.514

9.  Cytotoxic activity of cerium complexes with coumarin derivatives. Molecular modeling of the ligands.

Authors:  I Manolov; I Kostova; T Netzeva; S Konstantinov; M Karaivanova
Journal:  Arch Pharm (Weinheim)       Date:  2000-04       Impact factor: 3.751

10.  Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.

Authors:  U P Masche; K M Rentsch; A von Felten; P J Meier; K E Fattinger
Journal:  Eur J Clin Pharmacol       Date:  1999-01       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.